- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03879109
Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (GRECCAR15)
A Phase III Randomized Trial Evaluating Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (GRECCAR - PRODIGE - FRENCH)
GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous pelvic radiotherapy for the primary rectal cancer. This situation leads to a 20% higher risk of non-curative resection for the LRRC management (R1 status) impacting significantly the overall survival. The widespread use of neoadjuvant radiotherapy for primary rectal cancer introduces this new problem: the treatment of LRRC in previously irradiated area.
The objective of GRECCAR 15 is to assess the efficacy of neoadjuvant chemotherapy followed by pelvic reirradiation versus neoadjuvant chemotherapy alone on the rate of curative surgery (R0) in previously irradiated patients with LRRC.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The incidence of rectal cancer in the European Union is 15-25/100 000 per year. There is a 5-10% rate of locally recurrent rectal cancer (LRRC), with an overall survival rate of 40% at 5 years after complete resection. Curative surgery of LRRC requires multi-visceral resections which are associated with significant post-operative morbidity of 60%. Despite the combination of a potential curability and the high post-operative morbidity, there are currently neither good data from prospective randomized studies regarding optimum preoperative treatments for LRRC nor is there data assessing the efficacy of response to any such treatments. Moreover, the widespread use of neoadjuvant radiotherapy for primary cancer introduced a new problem: the treatment of LRRC in previously irradiated area. Some studies investigated various modalities of reirradiation and showed acceptable late toxicity and encouraging outcome. GRECCAR 15 would be the first prospective randomized trial so far to evaluate the interest of pelvic reirradiation for LRRC, in previously irradiated patients.
The objective is to assess the efficacy of neoadjuvant chemotherapy followed by pelvic reirradiation versus neoadjuvant chemotherapy alone on the rate of curative surgery (R0) in previously irradiated patients with LRRC.
Patients will be followed every 4 months during 2 years, and every 6 months the last year with chest, abdominal and pelvic scan and tumour markers.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Avignon, France
- Institut Sainte Catherine
-
Bordeaux, France
- CHU Bordeaux
-
Grenoble, France
- CHU Grenoble
-
Lille, France
- Centre Oscar Lambret
-
Lyon, France
- Hospices Civils de Lyon, HCL
-
Marseille, France
- Institut Paoli Calmette
-
Montpellier, France
- Institut Du Cancer de Montpellier
-
Nancy, France
- CHRU Nancy
-
Paris, France
- Groupe Hospitalier Paris Saint-Joseph
-
Rennes, France
- CHU Rennes
-
Rouen, France
- CHU Rouen
-
Saint-Herblain, France
- Institut de Cancérologie de l'Ouest
-
Toulouse, France
- CHU Toulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent
- Age ≥18 years
- LRRC (histologically proven) ≤ 15 cm from the anal verge
- First or second LRRC (histologically proven) ≤ 15 cm from the anal verge
- Previous pelvic irradiation for the primary rectal cancer or primary recurrence (25-50.4Gy)
- No distant metastasis
- Resectable locally recurrent rectal cancer (according to the International consensus, absolute contraindications for resectabililty are bilateral sciatic nerve involvement, circumferential bone involvement, high sacral involvement requiring total sacrectomy; relative contraindications for resectabilty are sciatic notch involvement and encasement external iliac vessels)
- Adequate hematologic function : Hemoglobin ≥ 9 g/dL, leukocytes ≥ 4000/mm3, neutrophil count ≥ 1500/mm3, blood platelets ≥ 100 000/mm3
- Adequate hepatic function : total bilirubin ≤ 1,5 x ULN, ASAT et ALAT ≤ 3 x ULN, alkalin phosphatases ≤ 3 x ULN
- Adequate renal function : creatinine clearance ≥ 30 ml/min
- ECOG performance status < 2
- Women not sterilized by the first treatment (ovarian transposition) and males (and their female partners) patients agree to use two methods of effective contraception (one of them being a barrier method) during the study, for at least 6 months for men and for women after the last administration of study treatment
- Patient affiliated to a social security system or beneficiary of the same
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
Exclusion Criteria:
- Recurrent rectal cancer after local excision
- Concomitant cancer or medical history of cancer within 5 years other than cancers treated in situ (cervical carcinoma or basocellular carcinoma or spinocellular carcinoma)
- Contraindication for chemotherapy Contraindication for chemotherapy (refer to Summary of characteristics of the products of the study drugs available at http://base-donnees-publique.medicaments.gouv.fr) or radiotherapy or surgery
- Symptomatic cardiac or coronary insufficiency
- Personal or family history of long QT syndrome congenital
- ECG at screening or baseline (predose) with QT/QTc > 450 msec (male) or QT/QTc > 470 msec (female)
- Chronic inflammatory bowel disease and/or bowel obstruction
- Patients with hypocalcemia, hypokalemia, hypomagnesemia.
- Progressive active infection (HIV or chronic hepatitis B or C) or any other severe medical condition that may preclude the delivery of treatment
- Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia ≥ 16 ng/mL)
- If contraindication to FOLFIRINOX, possibility to administred FOLFOX or FOLFIRI +/-EGFR (Contraindication to oxaliplatin: peripheral neuropathy > grade 1 (CTCAE grading system v5.0)
- Peripheral neuropathy > grade 1 (CTCAE grading system v5.0)
- Concomitant treatment with millepertuis, yellow fever vaccine, live attenuated vaccine, phenytoin, warfarin or sorivudine (or chemically equivalent)
- Pregnant or breast-feeding woman
- Persons deprived of liberty or under guardianship or incapable of giving consent
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule, as assessed by investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Induction Chemotherapy followed by Pelvic reirradiation
Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week. |
Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
Surgery will be performed at:
Surgical procedures are defined into three categories:
|
Active Comparator: Arm B: Chemotherapy alone
Protocol of chemotherapy FOLFIRINOX*, 6 cycles :
|
Surgery will be performed at:
Surgical procedures are defined into three categories:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of curative surgery
Time Frame: At surgery, expected average 6 to 8 weeks after neoadjuvant treatment
|
To determine the rate of R0 resection
|
At surgery, expected average 6 to 8 weeks after neoadjuvant treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Free Survival
Time Frame: From surgery until 3 years of follow-up
|
Rate of disease-free survival at 3 years
|
From surgery until 3 years of follow-up
|
Overall Survival
Time Frame: From surgery until 3 years of follow-up
|
Rate of overall survival at 3 years
|
From surgery until 3 years of follow-up
|
Surgical morbidity
Time Frame: From surgery until 30 days after surgery
|
To analyse surgical morbidity (Dindo classification) during first 30 days after the surgery
|
From surgery until 30 days after surgery
|
Surgical mortality
Time Frame: From surgery until 30 days after surgery
|
To analyse surgical mortality (Dindo classification) during first 30 days after the surgery
|
From surgery until 30 days after surgery
|
Compliance to treatment
Time Frame: From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment
|
Proportion of patients receiving full allocated neoadjuvant treatment
|
From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment
|
Proportion of good tumor response
Time Frame: At 6 weeks (Arm A) and 4 weeks (Arm B) after neoadjuvant treatment
|
Rate of tumor with a decreasing size of 50% at least after preoperative treatment at MRI
|
At 6 weeks (Arm A) and 4 weeks (Arm B) after neoadjuvant treatment
|
Quality of life (QLQ CR-30)
Time Frame: Before neoadjuvant treatment, before surgery, 4 months, one year and two years after surgery
|
The scores of questionnaire QLQ C-30 will be examined The EORTC QLQ-C30 is a patients self-rating questionnaire that measures physical, role, social, emotional, and cognitive functions as well as overall QoL.
Scores can be linearly transformed to provide a score from 0 to 100.
Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales.
|
Before neoadjuvant treatment, before surgery, 4 months, one year and two years after surgery
|
Quality of life (QLQ CR-29)
Time Frame: Before neoadjuvant treatment, before surgery, 4 months, one year and two years after surgery
|
The scores of questionnaire QLQ CR-29 will be examined.
The EORTC QLQ-CR29 has five functional and 18 symptom scales.
Scores can be linearly transformed to provide a score from 0 to 100.
Higher scores represent better functioning on the functional scales and a higher level of symptoms of the symptom scales.
|
Before neoadjuvant treatment, before surgery, 4 months, one year and two years after surgery
|
Tolerance to treatment
Time Frame: From beginning of neoadjuvant treatment until 1 year after surgery
|
Number of patients with adverse events
|
From beginning of neoadjuvant treatment until 1 year after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christophe LAURENT, University Hospital, Bordeaux
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2017/52
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
National Cancer Institute (NCI)TerminatedMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
Clinical Trials on Chemotherapy FOLFIRINOX, 6 cycles
-
North Eastern German Society of Gynaecological...Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNot yet recruitingOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
-
AGO Study GroupActive, not recruitingOvarian CancerUnited States, France, Germany, Austria, Sweden, Denmark, Italy, United Kingdom
-
St. Jude Children's Research HospitalCompleted
-
Ruijin HospitalRecruiting
-
Second Affiliated Hospital, School of Medicine,...UnknownNasopharyngeal Carcinoma | Neoadjuvant ChemotherapyChina
-
Medical University of South CarolinaTerminatedAdenocarcinoma of Head of PancreasUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruitingLocally Advanced Nasopharyngeal CarcinomaChina
-
University Hospital, RouenFederation Francophone de Cancerologie Digestive; UNICANCER; Federation of Research... and other collaboratorsUnknownResectable Pancreatic Duct AdenocarcinomaFrance
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Not yet recruitingPancreatic Ductal Adenocarcinoma | Oligometastatic DiseaseUnited States
-
Shandong Provincial HospitalUnknownHepatosplenic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ALK-negative Anaplastic Large Cell Lymphoma | Angioimmunoblastic T Cell Lymphoma | Enteropathy Associated T Cell Lymphoma | Subcutaneous Panniculitis Like T Cell LymphomaChina